supplementary figure 1 summary of overall study design and ...€¦ · supplementary figure 3....

123
Supplementary Figure 1. Summary of overall study design and workflow for meta-analyses. All numbers provided represent the maximum number specific for that trait (BMI-red, WCadjBMI-blue, and WHRadjBMI-green) and strata (EUR-European descent participants, nonEUR-excluding European descent participants). Three studies provided GWAS data for EUR and nonEUR participants.

Upload: others

Post on 28-Jul-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

  • Supplementary Figure 1. Summary of overall study design and workflow for meta-analyses. All numbers providedrepresent the maximum number specific for that trait (BMI-red, WCadjBMI-blue, and WHRadjBMI-green) and strata (EUR-European descent participants, nonEUR-excluding European descent participants). Three studies provided GWAS data for EUR and nonEUR participants.

  • Supplementary Figure 2. Summary plots of discovery meta-analysis for Approach 1 primary meta-analyses. (a)Manhattan plot showing the loci identified in Approach 1 in primary meta-analyses, used to identify significant main effects loci (SNPadjSMK), in the primary meta-analyses association –log10P-values for BMI-red, WCadjBMI-blue, and WHRadjBMI-green; (b) Manhattan plot showing the loci identified in Approach 1 excluding known regions +/- 500 kb andlabeled with the nearest gene to the index SNP; (c) QQ-plot showing the Approach 1 P-values as observed against thoseexpected under the null for each phenotypes separately (colored); (d) QQ-plot for Approach 1 after excluding knownassociation regions. *PSMB10 locus is >500 +/- kb from previously identified index SNPs, but is not independent of known GWAS signals.

  • Supplementary Figure 3. Regional association plots for Approach 1 primary meta-analyses. Regional association plotsfor all novel loci identified in Approach 1 (SNPadjSMK) in primary meta-analyses for BMI: (a) rs10929925, (b) rs6794880; WCadjBMI: (c) rs17396340, (d) rs6743226, (e) rs4378999, (f) rs7697556, (g) rs10269774, (h) rs6470765, (i) rs9409082, (j) rs6012558; and WHRadjBMI: (k) rs1049281, and ordered as they appear in Table 1. LD has beencalculated using the combined ancestries from the 1000 Genomes Phase 1 reference panel. For comparison, each plot highlights the p-value for the tag SNP in Approach 1 (PadjSMK), Approach 2 (Pjoint), Approach 3 (Pint), current smokers (PSMK), and in nonsmokers (PnonSMK).

  • a. BMI: rs10929925 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    LINC01248

    SOX11

    LINC01105

    LOC400940

    LINC01247

    5.8 6 6.2 6.4 6.6Position on chr2 (Mb)

    Coronary artery calcification

    Chronic kidney disease

    s disease

    0.2

    0.4

    0.6

    0.8

    r2

    justanneTypewritten Text

    justanneTypewritten Text

    justanneTypewritten Text

    justanneTypewritten Text

    justanneTypewritten Text

  • b. BMI: rs6794880 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    LINC00971

    84 84.2 84.4 84.6 84.8Position on chr3 (Mb)

    Obesity−related traits Brain structure

    0.2

    0.4

    0.6

    0.8

    r2

  • c. WCadjBMI: rs17396340 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    PIK3CD

    CLSTN1

    CTNNBIP1

    LZIC

    NMNAT1

    RBP7

    UBE4B KIF1B

    PGD

    APITD1

    APITD1−CORT

    CORT

    DFFA

    PEX14

    CASZ1

    9.8 10 10.2 10.4 10.6Position on chr1 (Mb)

    Alcohol dependence (age at onset)

    0.2

    0.4

    0.6

    0.8

    r2

  • d. WCadjBMI: rs6743226 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    KIF1A

    AGXT

    C2orf54

    LOC200772

    SNED1

    MTERFD2

    PASK

    PPP1R7

    ANO7

    HDLBP

    SEPT2

    FARP2

    STK25

    BOK−AS1

    BOK

    THAP4

    ATG4B

    DTYMK

    ING5

    D2HGDH

    GAL3ST2

    241.8 242 242.2 242.4 242.6Position on chr2 (Mb)

    Height

    Height

    Height

    Brain structure

    HIPadjBMI

    Height

    0.2

    0.4

    0.6

    0.8

    r2

  • e. WCadjBMI: rs4378999 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    MIR4787

    DOCK3

    MANF

    RBM15B

    VPRBP

    RAD54L2

    TEX264

    50.8 51 51.2 51.4 51.6Position on chr3 (Mb)

    Height

    Height

    0.2

    0.4

    0.6

    0.8

    r2

  • f. WCadjBMI: rs7697556 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    ADAMTS3 COX18

    ANKRD17

    73.2 73.4 73.6 73.8 74Position on chr4 (Mb)

    Metabolite levels

    HIPadjBMI

    Height

    Height

    Lipid metabolism phenotypes

    0.2

    0.4

    0.6

    0.8

    r2

  • g. WCadjBMI: rs10269774 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    CYP51A1

    LRRD1 KRIT1

    ANKIB1 GATAD1

    PEX1

    RBM48

    MGC16142

    FAM133B

    FAM133DP

    CDK6

    LOC101927497

    SAMD9

    91.8 92 92.2 92.4 92.6Position on chr7 (Mb)

    1 GWAS hitomitted

    Height

    Height

    Height

    Height

    Height

    HIPadjBMI

    0.2

    0.4

    0.6

    0.8

    r2

  • h. WCadjBMI: rs6470765 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    LINC00977 GSDMC FAM49B

    MIR5194

    ASAP1

    ASAP1−IT2

    130.4 130.6 130.8 131 131.2Position on chr8 (Mb)

    HIPadjBMI

    Height

    Inflammatory bowel disease

    Height

    0.2

    0.4

    0.6

    0.8

    r2

  • i. WCadjBMI: rs9409082 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    ●●

    FKTN

    TAL2 TMEM38B

    MIR8081

    LOC100996590

    108.6 108.8 109 109.2 109.4Position on chr9 (Mb)

    2 GWAS hitsomitted

    Menarche (age at onset)

    Menarche (age at onset)

    Height

    Menarche and menopause (age at onset)

    Height

    Menarche (age at onset)

    Menarche (age at onset)

    0.2

    0.4

    0.6

    0.8

    r2

  • j. WCadjBMI: rs6012558 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    PREX1 ARFGEF2

    LOC102723483

    CSE1L

    STAU1 DDX27

    ZNFX1

    ZFAS1

    SNORD12C

    SNORD12B

    SNORD12

    KCNB1

    47.2 47.4 47.6 47.8 48Position on chr20 (Mb)

    QT interval

    Obesity−relat

    Height

    Height

    0.2

    0.4

    0.6

    0.8

    r2

  • k. WHRadjBMI: rs1049281 −

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    8 genesomitted

    DDR1

    MIR4640

    GTF2H4

    VARS2

    SFTA2

    DPCR1

    MUC21

    MUC22

    HCG22

    C6orf15

    PSORS1C1

    CDSN

    PSORS1C2

    CCHCR1

    TCF19

    POU5F1

    PSORS1C3

    HCG27

    HLA−C HLA−B

    MIR6891

    MICA

    HCP5

    HCG26

    MICB

    MCCD1

    DDX39B

    ATP6V1G2−DDX39B

    SNORD117

    SNORD84

    ATP6V1G2

    NFKBIL1

    LTA

    TNF

    LTB

    AIF1

    PRRC2A

    MIR6832

    BAG6

    APOM

    C6orf47

    GPANK1

    CSNK2B

    LY6G5B

    LY6G5C

    ABHD16A

    LY6G6F

    LY6G6E

    LY6G6D

    C6orf25

    CLIC1

    MSH5

    VWA7

    30.8 31 31.2 31.4 31.6Position on chr6 (Mb)

    20 GWAS hitsomitted

    Height

    Renal function−related traits (eGRFcrea)

    Height

    Diastolic blood pressure

    Systolic blood pressure

    Pubertal anthropometrics

    Renal function−related traits (sCR)

    Height

    Hematology traits Menopause (age at onset)

    0.2

    0.4

    0.6

    0.8

    r2

    justanneTypewritten Text

    justanneTypewritten Text

  • Supplementary Figure 4. Summary plots of discovery meta-analysis for Approach 2 primary meta-analyses. (a) Manhattan plot showing the loci identified in Approach 2 in primary meta-analyses, used to identify significant joint main+interaction effects loci (SNPjoint), in the primary meta-analyses association –log10P-values for BMI-red, WCadjBMI-blue, and WHRadjBMI-green; (b) Manhattan plot showing the loci identified in Approach 2 excluding known regions +/- 500 kb and labeled with the nearest gene to the index SNP; (c) QQ-plot showing the Approach 2 P-values as observed against those expected under the null for each phenotypes separately (colored); (d) QQ-plot for Approach 2 after excluding known association regions.

  • Supplementary Figure 5. Regional association plots for Approach 2 primary meta-analyses. Regional association plotfor all novel loci identified in Approach 2 (SNPjoint) in the primary meta-analyses for BMI: (a) rs10929925, (b) rs13069244; WCadjBMI: (c) rs17396340, (d) rs6743226, (e) rs7697556, (f) rs9408815, and WHRadjBMI: (g) rs1049281,and ordered as they appear in Table 1. LD has been calculated using the combined ancestries from the 1000 Genomes Phase 1 reference panel. For comparison, each plot highlights the p-value for the tag SNP in Approach 1 (PadjSMK), Approach 2 (Pjoint), Approach 3 (Pint), current smokers (PSMK), and in nonsmokers (PnonSMK).

    justanneTypewritten Text

  • a. BMI: rs10929925 − Approach 2

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●●

    ●●●●●●●●●

    ●●●●●

    ●●

    ●●●●

    ●●●

    ●●●

    ●●●●●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●●●●●●

    ●●●●●

    ●●

    ●●

    ●●●●●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●●

    ●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●●●●●●●

    ●●●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●●●●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●●

    ●●●●●

    ●●

    ●●

    ●●●

    ●●●●●●●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●●●●●

    ●●●●●

    ●●

    ●●●●●●●●●

    ●●●●●●

    ●●●

    ●●●●

    ●●●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●●●●●●●●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●●

    ●●

    ●●●●

    ●●●●

    ●●●●●●●●●●

    ●●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●●●●

    ●●●

    ●●●

    ●●●●●●

    ●●●●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●●●●●

    ●●●●●●

    ●●●

    ●●

    ●●●●●●●●●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●●●●

    ●●●

    ●●●

    ●●●●●●

    ●●●●●●

    ●●

    ●●●

    ●●●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●

    LINC01248

    SOX11

    LINC01105

    LOC400940

    LINC01247

    5.8 6 6.2 6.4 6.6Position on chr2 (Mb)

    Coronary artery calcification

    Chronic kidney disease

    s disease

    0.2

    0.4

    0.6

    0.8

    r2

  • b. BMI: rs13069244 − Approach 2

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●

    ●●

    ●●●

    ●●●●●●●●

    ●●●●

    ●●●●●

    ●●●

    ●●●●

    ●●●●●●●

    ●●●

    ●●

    ●●

    ●●●●●●●●●●

    ●●

    ●●●●

    ●●●●●●●

    ●●●●●●●●●●

    ●●●●●

    ●●● ●●●●

    ●●

    ●●

    ●●●●

    ●●●●●

    ●●

    ●●●●●●●●●●●

    ●●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●

    ●●●●●

    ●●

    ●●

    ●●●

    ●●●●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    TTC14

    CCDC39

    LOC101928882 FXR1

    DNAJC19

    SOX2−OT

    180 180.2 180.4 180.6 180.8Position on chr3 (Mb)

    0.2

    0.4

    0.6

    0.8

    r2

  • c. WCadjBMI: rs17396340 − Approach 2

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●

    ●●●

    ●●●

    ●● ●

    ●● ●● ●

    ●● ●

    ●●

    ●●●

    ●●●

    ●●●●●

    ●●●●●

    ●●

    ●●●●

    ●●●●●●●

    ●●

    ●●●

    ●●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●●●

    ● ●

    ●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●●

    ●●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●● ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●● ●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●●●●●

    ●●

    ●●●

    ●●

    ●●

    PIK3CD

    CLSTN1

    CTNNBIP1

    LZIC

    NMNAT1

    RBP7

    UBE4B KIF1B

    PGD

    APITD1

    APITD1−CORT

    CORT

    DFFA

    PEX14

    CASZ1

    9.8 10 10.2 10.4 10.6Position on chr1 (Mb)

    Alcohol dependence (age at onset)

    0.2

    0.4

    0.6

    0.8

    r2

    justanneTypewritten Text

    justanneTypewritten Text

  • d. WCadjBMI: rs6743226 − Approach 2

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●●

    ●●●●●

    ●●●

    ●●●

    ●●●

    ●●●●●●●

    ●●●

    ●●●●●●●

    ●●●●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●●●●●●●

    ● ●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ● ●

    ●●

    ●●

    ●●

    KIF1A

    AGXT

    C2orf54

    LOC200772

    SNED1

    MTERFD2

    PASK

    PPP1R7

    ANO7

    HDLBP

    SEPT2

    FARP2

    STK25

    BOK−AS1

    BOK

    THAP4

    ATG4B

    DTYMK

    ING5

    D2HGDH

    GAL3ST2

    241.8 242 242.2 242.4 242.6Position on chr2 (Mb)

    Height

    Height

    Height

    Brain structure

    HIPadjBMI

    Height

  • e. WCadjBMI: rs7697556 − Approach 2

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●●●

    ●●●●●●●●●●●●●●●●●

    ●●●●●●●●

    ●●●●●●●●●●●●●●●●●●

    ●●●●●●

    ●●●●●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●●●●●●●●●●●

    ●●

    ●●●●●

    ● ●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●●

    ●●

    ●● ●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●●●

    ●●●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●●●●●

    ●●●

    ●●●

    ●●●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●●

    ●●

    ●●●●●●●

    ●●●

    ●●●●●●●●

    ●●

    ●●●●●●●●●

    ●●●●

    ●●●●●●●●●●●

    ●●

    ●●●●●●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ADAMTS3 COX18

    ANKRD17

    73.2 73.4 73.6 73.8 74Position on chr4 (Mb)

    Metabolite levels

    HIPadjBMI

    Height

    Height

    Lipid metabolism phenotypes

    0.2

    0.4

    0.6

    0.8

    r2

  • f. WCadjBMI: rs9408815 − Approach 2

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●●

    ●●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●●●●●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●●

    ●●●

    ●●●●●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●●●●●●●●

    ●●●●●●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●●●●●

    ●●●●●●●●●●●●

    ●●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●●●●

    ●●●●●●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●●●●●●●

    ●●

    ●●●●●

    ●●●●●●●●●

    ●●●

    ●●

    ●●●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●●●

    ●●●●●●●●

    ●●●●

    ●●●●●●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●●

    ●●

    ●●

    ● ●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    FKTN

    TAL2

    TMEM38B MIR8081

    LOC100996590

    108.4 108.6 108.8 109 109.2Position on chr9 (Mb)

    2 GWAS hitsomitted

    Menarche (age at onset)

    Menarche (age at onset)

    Height

    Menarche and menopause (age at onset)

    Height

    Menarche (age at onset)

    Menarche (age at onset)

    0.2

    0.4

    0.6

    0.8

    r2

  • g. WHRadjBMI: rs1049281 − Approach 2

    0

    2

    4

    6

    8

    10

    −lo

    g 10(

    p−va

    lue)

    0

    20

    40

    60

    80

    100

    Recom

    bination rate (cM/M

    b)

    ●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●●

    ●●●

    ●●●

    ●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●●

    ●●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●●

    ●●●●●●●●●

    ●●●●●●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●●●●

    ●●

    ●●●●

    ●●●●●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●●

    ●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●●

    ●●

    ●●

    ●●●●●●●●●●●●●●●●●●

    ●●

    ●●

    ●●●●●●

    ●●●●

    ●●●●●●●●●●●

    ●●●●

    ●●●●●●●

    ●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●●

    ●●●

    ●●●

    ●●●●●

    ●●

    ●●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●●

    ●●●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●●●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●●●

    ●●

    ●●●

    ●●●●●

    ●●

    ●●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●● ●

    ● ●

    ● ●

    ●●●●●●●●●

    ●●●

    ● ●●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●●●●

    ●●●●●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●

    8 genesomitted

    DDR1

    MIR4640

    GTF2H4

    VARS2

    SFTA2

    DPCR1

    MUC21

    MUC22

    HCG22

    C6orf15

    PSORS1C1

    CDSN

    PSORS1C2

    CCHCR1

    TCF19

    POU5F1

    PSORS1C3

    HCG27

    HLA−C HLA−B

    MIR6891

    MICA

    HCP5

    HCG26

    MICB

    MCCD1

    DDX39B

    ATP6V1G2−DDX39B

    SNORD117

    SNORD84

    ATP6V1G2

    NFKBIL1

    LTA

    TNF

    LTB

    AIF1

    PRRC2A

    MIR6832

    BAG6

    APOM

    C6orf47

    GPANK1

    CSNK2B

    LY6G5B

    LY6G5C

    ABHD16A

    LY6G6F

    LY6G6E

    LY6G6D

    C6orf25

    CLIC1

    MSH5

    VWA7

    30.8 31 31.2 31.4 31.6Position on chr6 (Mb)

    20 GWAS hitsomitted

    Height

    Renal function−related traits (eGRFcrea)

    Height

    Diastolic blood pressure

    Systolic blood pressure

    Pubertal anthropometrics

    Renal function−related traits (sCR)

    Height

    Hematology traits Menopause (age at onset)

    0.2

    0.4

    0.6

    0.8

    r2

  • Supplementary Figure 6. Regional association plots for Approaches 1-3 secondary meta-analyses. Regional association plot for additional novel loci identified in Approaches 1 (SNPadjSMK), Approach 2 (SNPjoint), or Approach 3 (SNPint) secondary meta-analyses for BMI: (a) rs2481665, (b) rs2173039, (c) rs12629427; WCadjBMI: (d) rs1545348, (e) rs6076699 (Approach 2), (f) rs6076699 (Approach 3), (g) rs670752; and WHRadjBMI: (h) rs589428, (i) rs1856293, (j) rs2001945, (k) rs17065323. LD has been calculated using the combined ancestries from the 1000 Genomes Phase 1 reference panel. For comparison, each plot highlights the p-value for the tag SNP in Approach 1 (PadjSMK), Approach 2 (Pjoint), Approach 3 (Pint), current smokers (PSMK), and in nonsmokers (PnonSMK). P-values are shown from the strata in which the signal was identified (e.g. European-only women). EUR- European-only meta-analyses; ALL- all ancestries combined meta-analyses.

    justanneTypewritten Text

  • a.

    ●●●

    MGC34796

    TM2D1

    INADL L1TD1

    KANK4

    USP1

    DOCK7

    ANGPTL3

  • b. LL

    ●●●

    EPHA3

  • c.

    ●●●

    EPHA3

  • d.

    ●●●

    RAI14

    TTC23L

    RAD1

    BRIX1

    DNAJC21

    AGXT2

    PRLR

  • e.

    ●● ●

    ●●●●

    ●●●●●

    ●●●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●●●

    ●●●

    ●●●●●●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●●●●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●●●●●●●●●

    ●●●●

    ●●

    ●●

    ●●●●●

    ●●●●●●●

    ●●●●●●●●●●

    ●●●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●●●

    ●●●

    ●●●●●●●●●●●●

    ●●

    ●●●

    ●●

    ●●●●●

    ●●●●●

    ●●●

    ●●

    ●●

    ●●●●

    ●●●●

    ●●

    ●●●

    ●●●●●●●●

    ●●●

    ●●

    ●●●●

    ●●●●●●●●●●●●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●●●

    ●●

    ●●●●●●●●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●●●●●

    ●●●●

    ●●●●

    ●●●

    ●●

    ●●●●

    ●●●

    ●●●●●●●

    ●●

    ●●●

    ●●

    ●●●●

    ●●●

    ●●●●●●●●●●

    ●●

    ●●

    ●●●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●●●●●●

    ●●

    ●●●●

    ●●●

    ●●

    ●●

    ●●●●●●●●●●●●

    ●●●●●●●●●●●

    ●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●●●●

    ●●●●

    ●●●●●●●●

    ●●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●●●●●

    ●●●●●●

    ●●●●●●●

    ●●●●●

    ●●●

    ●●●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●●●●

    ●●●●●

    ●●●●●

    ●●

    ●●●●●●●●●●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●●●●●●●●

    ●●

    ●●●●●

    ●●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●●●●

    ●●

    ●●●●●

    ●●

    ●●●

    ●●

    ●●●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●●●●

    ●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●●

    ●●●●

    ●●

    SMOX

    LOC728228

    ADRA1D

    PRNP

    PRND

    PRNT

    RASSF2 SLC23A2

  • f.

    ●●●

    SMOX

    LOC728228

    ADRA1D

    PRNP

    PRND

    PRNT

    RASSF2 SLC23A2

  • g. LL

    ●●●

    LINC00882

    LINC00883

    CCDC54

    LOC101929607

    BBX LINC00635

    LINC00636

    CD47

  • h.

    ●●●

    MICA

    HCP5

    HCG26

    MICB

    MCCD1

    DDX39B

    ATP6V1G2−DDX39B

    SNORD117

    SNORD84

    ATP6V1G2

    NFKBIL1

    LTA

    TNF

    LTB

    AIF1

    PRRC2A

    MIR6832

    BAG6

    APOM

    C6orf47

    GPANK1

    CSNK2B

    LY6G5B

    LY6G5C

    ABHD16A

    LY6G6F

    LY6G6E

    LY6G6D

    C6orf25

    CLIC1

    MSH5

    SAPCD1

    VWA7

    VARS

    LSM2

    HSPA1L

    HSPA1A

    HSPA1B

    C6orf48

    SNORD48

    SNORD52

    NEU1

    SLC44A4

    EHMT2

    C2

    ZBTB12

    LOC102060414

    CFB

    NELFE

    MIR1236

    SKIV2L

    DXO

    STK19

    C4A

    C4B

    C4B_2

    CYP21A2

    TNXB

    ATF6B

    FKBPL

    PRRT1

    LOC100507547

    PPT2

    PPT2−EGFL8

    EGFL8

    AGPAT1

    MIR6721

    RNF5

    PBX2

    NOTCH4

    C6orf10

  • i.

    ●●

    ●●

    ● ●●

    ●●●

    ●●

    ●●●●●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●●●●●●●●●

    ●●●●●

    ●●●●●

    ●●●●●●●●●

    ●●

    ●●●

    ●●

    ●●●●●

    ●●●●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●●●●●●●●

    ●●●●●●●●●●●●●●●

    ●●●

    ●●●●●●●●●

    ●●●

    ●●

    ●●●●●

    ●●●●●

    ●●

    ●●●●●●●

    ●●●

    ●●●●●●

    ●●●

    ●●●

    ●●

    ●●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●●●●●●●●●●●

    ●●●●●●●

    ●●●

    ●●●

    ●●●●●●●●●●

    ●●●●●●●●

    ●●

    ●●●●●●

    ●●

    ●●●●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●

    ●●●

    ●●●

    ●●●●●●●

    ●●

    ●●●●

    ●●

    ●●●●

    ●●●●●●●●●●●●●●●

    ●●●

    ●●●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●●●●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●

    ●●●●●●

    ●●●●

    ●●●●●

    ●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●●●●●●●●●●●

    ●●●●●●●●●●●●●●●

    ●●

    ●●●●●●●●●●●●●●●●●●●●

    ●●●●●

    ●●

    ●●●●

    ●●●●●●

    ●●

    ●●●●●

    ●●

    ●●●●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●●

    ●●

    ●●●●

    ●●

    ●●●●●●

    ●●

    ●●

    ●●●●●●

    ●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●●●●●●●●

    ●●●●

    ●●●●●●●●●●●●

    ●●●●

    ●●●●●●●●●●●

    ●●●●●

    ●●●

    ●●●

    ●●

    ●●

    ●●●●

    ●●

    ●●●●●

    ●●●

    ●●●●

    ●●●●●●●●●●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●

    ●●●

    ●●

    ●●

    ●●●

    ●●●●

    ●●

    ●●

    ●●●●●

    ●●

    ●●

    ●●

    VNN1

    VNN3

    VNN2

    SLC18B1

    RPS12

    SNORD101

    SNORD100

    SNORA33

    LINC00326 EYA4

    EYA4−AS1

  • j. LL

    ●●●

    ZNF572

    SQLE

    KIAA0196

    NSMCE2 TRIB1 LINC00861

  • k.

    ●●●

    ENOX1 CCDC122

    LACC1

    LINC00284 SMIM2−AS1

    SMIM2

    SMIM2−IT1

    MIR8079

    SERP2

    TUSC8

    TSC22D1

  • Supplementary Figure 7. Simulation-based estimation of type 1 error using QQ plots. Shown are the QQ plots of simulation results for Approach 1 (adjusted effect), Approach 2 (joint effect),

    Approach 3 and 4 (interaction effects). The simulation was based on MAF=0.05, 50,000 smokers and

    180,000 nonsmokers.

  • Supplementary Fig. 8. Heatmap of –log10P-values for SNPadjSMK, SNPjoint, and SNPint models. We have included each variant identified in the

    all ancestries analysis which was significant for Approaches 1-3. Strength of color represents the –log10 P-value from the all ancestries,

    combined sexes meta-analysis for (a) BMI in red, (b) WCadjBMI in blue, and (c) WHRadjBMI in green.

  • Supplementary Figure . Summary plots of discovery meta-analysis for Approach 3 primary meta-analyses. (a) Manhattan plot showing the loci identified in Approach 3 in primary meta-analyses, used to identify significant interaction effects loci (SNPint), in the primary meta-analyses association –log10P-values for BMI-red, WCadjBMI-blue, and WHRadjBMI-green; (b) Manhattan plot showing the loci identified in Approach 3 excluding known regions +/- 500 kb and labeled with the nearest gene to the index SNP; (c) QQ-plot showing the Approach 3 P-values as observed against those expected under the null for each phenotypes separately (colored); (d) QQ-plot for Approach 3 after excluding known association regions.

  • Supplementary Figure . Regional association plots for Approach 3 primary meta-analyses. Regional association plot for all loci identified in Approach 3 in primary meta-analyses, used to identify significant interaction (SNPint), in the primary meta-analyses for BMI: (a) rs336396, (b) rs12902602; and WCadjBMI: (c) rs4141488, and ordered as they appear in Table 3. LD has been calculated using the combined ancestries from the 1000 Genomes Phase 1 reference panel. For comparison, each plot highlights the p-value for the tag SNP in Approach 1 (PadjSMK), Approach 2 (Pjoint), Approach 3 (Pint), current smokers (PSMK), and in nonsmokers (PnonSMK).

    justanneTypewritten Text

  • a. Approach 3

    ●●●

    IL15 INPP4B

    0.2

    0.4

    0.6

    0.8

    r2

    justanneTypewritten Text

    justanneTypewritten Text

  • b. Approach 3

    ●●●

    ACSBG1

    DNAJA4

    WDR61

    CRABP1

    IREB2

    HYKK

    PSMA4

    CHRNA5

    CHRNA3

    CHRNB4 LOC646938

    ADAMTS7

    MORF4L1

    CTSH

    RASGRF1

    0.2

    0.4

    0.6

    0.8

    r2

  • c. Approach 3

    ●●●

    C16orf72 MIR548X MIR7641−2 GRIN2A

    0.2

    0.4

    0.6

    0.8

    r2

    justanneTypewritten Text

  • Supplementary Figure . Forest plot for significant loci stratified by smoking status. Estimated effects (β ± 95% CI) for smokers (N upto 51,080) and nonsmokers (N up to 190,178) per risk allele for (a) BMI, (b) WCadjBMI, and (c) WHRadjBMI for the most significant variant for each locus identified in the primary meta-analyses (combined ancestries and combined sexes) for Approaches 1 (SNPadjSMK), 2 (SNPjoint) and 3 (SNPint). Loci are grouped by those with greater effect in nonsmokers, then smokers and then ordered by magnitude of effect in smokers and labeled with the nearest gene.

  • Supplementary Figure 1 . Estimated effects (β ± 95% CI) in smokers (N up to 51,080) and nonsmokers (N up to 190,178) per risk allele for (a) BMI, (b) WCadjBMI, and (c) WHRadjBMI for the most significant variant for each locus identified in the secondary meta-analyses (sex-stratified and European-only analyses) for Approaches 1 (SNPadjSMK), 2 (SNPjoint) and 3 (SNPint).

  • Supplemen